| abstract |
The present invention provides a compound having the following structure,nOr a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or a pharmaceutically acceptable salt, wherein A and A' are independently C or N, wherein C is not Substituted or substituted by halo or C1-C6 alkyl; R and R0 are independently selected from the group consisting of H, C1-C6 alkyl, hydroxy (C1-C6 alkyl), phenyl (C1-C6) Alkyl) and -(CH2)nW, wherein W is a C3-C8 cycloalkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic ring containing 1-3 N, S and/or O atoms a group, -SO2-R', -NHSO2-R', -NR"SO2-R' and SR', wherein R' and R" are independently a C1-C6 alkyl group or a C3-C8 cycloalkyl group; The alkyl group, the cycloalkyl group, the heterocyclic group, the phenyl group, the naphthyl group or the heteroaryl group may each be unsubstituted or substituted with a phenyl group, a heteroaryl group or the like; or, R and R0 together with the N atom to which they are bonded may form. Monocyclic or bicyclic heterocyclic rings which may be unsubstituted or substituted by: (a) halo, hydroxy, heteroaryl, C1-C6 alkyl, C1-C6 alkoxy, etc., or (b)-( CH2)nW, wherein W is C3-C8 cycloalkyl, phenyl, etc.; R1 is H, halo or cyano; R2 and R2' are independently H, C1-C6 alkyl, cyanidena C1-C6 alkoxy group, a C1-C6 alkylthio group or a C3-C8 cycloalkyl group, wherein the alkyl group, the alkoxy group or the cycloalkyl group is optionally substituted by one or more fluorine atoms; X is a bond , -CO-, -CONH-, -SO2-, -SONH- or -(CH2)m-; R3 is H, C1-C4 alkyl, phenyl, naphthyl, containing 1-3 N atoms 5 or a 6-membered heteroaryl or heterocyclic group, a 5-membered heteroaryl or heterocyclic group, or (c) 2 O or S atoms and 0 to 2 N atoms; wherein the phenyl, naphthyl, heteroaryl Or the heterocyclic group is optionally substituted with an alkyl group, a substituent -Y-R4 and/or 1-4 substituents each independently selected from R5; the limitation is when X is -CO- or -SO2 - when R3 is not H; Y is a bond, -(CH2)m- or -O-; R4 is (a)H, C1-C6 alkyl, C3-C8 cycloalkyl, halo, pendant oxy , -OR6, -NR7R8, -SR6, -SOR9, -SO2R9, -COR6, -OCOR6, -COOR6, -NR6COR6, -CONR7R8, etc.; (b) phenyl or naphthyl, the phenyl and naphthyl groups are optionally 1-5 substituents selected from the group consisting of C1-C6 alkyl, C3-C8 cycloalkyl, halo, cyano, -OR6, -NR7R8, etc.; or (c) 3 to 8 member saturated or Partially unsaturated monocyclic heteroaryl; etc.; R6 is H, C1-C6 alkyl or C3-C8 ring R7 and R8 are each independently H, C1-C6 alkyl or C3-C8 cycloalkyl or together with the nitrogen atom to which they are attached form a 1-2 nitrogen atom or a nitrogen atom and an oxygen atom. a 4, 5 or 6 membered saturated heterocyclic ring, the C1-C6 alkyl group being optionally substituted by a C3-C8 cycloalkyl group, a halogen group or the like and the heterocyclic ring optionally having one or more C1-C6 alkyl groups or C3-C8 Cycloalkyl substituted; R9 is C1-C6 alkyl or C3-C8 cycloalkyl; and m and n are independently 0, 1, 2 or 3. The present invention also relates to pharmaceutically acceptable salts of such compounds and pharmaceutically acceptable solvates thereof; compositions containing such compounds; and the use of such compounds in the treatment of various diseases, particularly asthma and COPD Use. |